ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Sunday, 8 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results

Dr. Reddy's Laboratories Financial Results

Dr. Reddy's Laboratories reported FY26 consolidated revenue of ₹33,593.3 Crore and recommended a ₹8 dividend per share. Performance reflects lower generic sales and one-time impact costs.

Key figures
Value₹33,593 Cr
Source

BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Dr. Reddy's Laboratories Ltd: key numbers

Share price
₹1,373.00
Market cap
₹1,14,601 Cr
Revenue (annual)
₹33,700 Cr
Net profit (annual)
₹4,196 Cr
P/E (TTM)
40.9×Sector 43.0×
Promoter holding
26.63%-0.01% QoQ
FII holding
20.30%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Dr. Reddy's Laboratories Ltd

All →
09:47 IST BSE
Regulatory Approval

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Other financial results announcements

All →